Podocon-25 (podophyllum resin)

No dosing information is available for this tab.

Podophyllum resin is applied topically.

The drug usually is applied in the form of a 10-25% solution in compound benzoin tincture; the CDC, at least one manufacturer, and other experts recommend that these solutions only be applied by a health-care provider and not dispensed to the patient. Solutions containing lower concentrations of podophyllum resin (i.e., 0.5-2% ethanolic solutions) have been prepared extemporaneously for self-administration by patients+; however, safety and efficacy of these solutions have not been established.

Prior to application of podophyllum resin solution, the affected area should be thoroughly cleansed. The solution should then be applied sparingly to lesions, avoiding contact with normal tissue, and allowed to air dry. The skin adjacent to the area being treated may be protected by applying petrolatum or flexible collodion prior to application of the drug. Use of large amounts of the drug should be avoided, since systemic toxicity may occur.

Immediately after the prescribed period of treatment (usually 1-4 hours), the dried drug should be thoroughly removed from the area of application using alcohol or soap and water. Care must be taken to ensure that all of the drug has been removed. To determine the patient's sensitivity to the drug, the manufacturer of Podocon-25(R) recommends that the drug be removed within 30-40 minutes after the initial application; for subsequent application, the drug should be removed after the minimum time period required to produce the desired result (usually 1-4 hours). Warts generally become blanched within a few hours after application of the drug and become necrotic within 24-48 hours. After about 72 hours, the lesions begin to slough and gradually disappear without scarring.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Podophyllum resin is contraindicated during pregnancy.

Use of topical podophyllum resin during pregnancy has been associated with complications including birth defects, fetal death, and stillbirth. Intrauterine death has occurred following topical application of podophyllum resin to vulval warts during the 32nd week of pregnancy. Following topical application of the drug during the 23rd, 24th, 25th, 28th, and 29th weeks of pregnancy in one woman, minor fetal anomalies including preauricular skin tags and a simian crease on the left hand occurred. Following oral administration during pregnancy of a preparation containing podophyllum, possible adverse fetal effects of the drug have included skin tags on the ear and cheek, polyneuritis, limb malformations, and septal heart defects.

It is not known whether topically applied podophyllum resin is distributed into human milk. The drug is contraindicated in women who are breast-feeding.

No enhanced messaging available.